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Abstract
Introduction: The loss of E-cadherin based cell-cell contacts and tumor cell migration to the vasculature and
lymphatic system are hallmarks of metastasis of epithelial cancers. Type I gamma phosphatidylinositol phosphate
kinase (PIPKIg), an enzyme that generates phosphatidylinositol 4,5-bisphosphate (PI4,5P2) a lipid messenger and
precursor to many additional second messengers, was found to regulate E-cadherin cell-cell contacts and growth
factor-stimulated directional cell migration, indicating that PIPKIg regulates key steps in metastasis. Here, we assess
the expression of PIPKIg in breast cancers and have shown that expression correlated with disease progression and
outcome.
Methods: Using a tissue microarray, we analyzed 438 breast carcinomas for the levels of PIPKIg and investigated
the correlation of PIPKIg expression with patient survival via Kaplan-Meier survival analysis. Moreover, via
knockdown of the expression of PIPKIg in cultured breast cancer cells with siRNA, the roles of PIPKIg in breast
cancer migration, invasion, and proliferation were examined.
Results: Tissue microarray data shows that ~18% of the cohort immunostained showed high expression of PIPKIg.
The Kaplan-Meier survival analysis revealed a significant inverse correlation between strong PIPKIg expression and
overall patient survival. Expression of PIPKIg correlated positively with epidermal growth factor receptor (EGFR)
expression, which regulates breast cancer progression and metastasis. In cultured breast cancer cells, PIPKIg is
required for growth factor stimulated migration, invasion, and proliferation of cells.
Conclusions: The results reveal a significant correlation between PIPKIg expression and the progression of breast
cancer. This is consistent with PIPKIg ‘s role in breast cancer cell migration, invasion, and proliferation.
Introduction
Breast cancer is one of the most significant malignancies
of women [1,2]. Despite successful treatment of the pri-
mary malignancy, tumors relapse and subsequent metas-
tasis often occur at distant sites, including bone, lung,
liver, and brain [3-5]. The presence of breast cancer
metastasis significantly influences patients’ prognosis.
The five-year survival rate from breast cancer drops
from 96% to 75% with regional spread, and drops to
20% with distant spread [6,7]. Understanding the mole-
cular mechanism that regulates breast cancer metastasis
is critical to developing therapies to treat breast cancer
and increase the survival rate; and defining markers that
predict metastatic potential will be a key for defining
therapeutic approaches.
Phosphatidylinositol 4,5-bisphosphate (PI4,5P2)p l a y s
central roles in regulating cell migration, a key step of
cancer metastasis, by modulating adhesion turnover and
dynamic cytoskeleton rearrangements [8]. By interacting
with cofilin, PI4,5P2 regulates the elongation of newly
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any medium, provided the original work is properly cited.polymerized actin filaments via controlling cofilin cellu-
lar distribution and activation [9,10]. Including cofilin,
PI4,5P2 also regulates the reorganization of actin cytos-
keleton by associating with other proteins such as a-
actinin, WASP/N-WASP, gelsolin, profilin, and villin
[8,11]. Furthermore, PI4,5P2 regulates adhesion turnover
by binding to and modulating talin, vinculin, ezrin/
radixin/moesin, calpain, and other proteins involved in
adhesion dynamics [8,11].
Type I gamma phosphatidylinositol phosphate kinase
(PIPKIg) is one of the major enzymes in cells that gener-
ate PI4,5P2 by phosphorylation of phosphatidylinositol
(4)phosphate [12]. Via the spatial and temporal control
of PI4,5P2 synthesis, PIPKIg plays a key role in multiple
biological processes [8,13-18]. Loss of PIPKIg leads to
defects of cardiovascular and neuronal development,
which is consistent with changes in cadherin function
and cell migration [19]. PIPKIg is also required for the
integrity of the membrane cytoskeleton [20]. The PIPKIg
is alternatively spliced in cells, resulting in at least two
major variants, PIPKIg635 and PIPKIg661 (now named
PIPKIgi1 and PIPKIgi2), which differ by a 26 amino acid
C-terminal extension [21,22]. The short splicing variant
PIPKIgi1 is reported to be a major contributor of the
PI4,5P2 pool that supports G protein-coupled receptor-
mediated inositol 1,4,5-trisphosphate generation and
plays a critical role in Ca
2+ flux [23]. Unlike PIPKIgi1,
PIPKIgi2 binds to talin via the 26 amino acid C-terminal
extension in a process regulated by tyrosine phosphory-
lation, targeting PIPKIgi2 to adhesions [17,24]. The
phosphorylation is mediated by both growth factor
receptors and by the non-receptor tyrosine kinase, Src
[8,17,18]. By generating PI4,5P2 and regulating talin
assembly, PIPKIgi2 modulates nascent adhesion forma-
tion at the leading edge to facilitate cell migration. Spe-
cifically, the PIPKIgi2 regulates epidermal and other
growth factor stimulated chemotaxis [25], a process key
to intravasation of cancer cells where cells migrate into
the vasculature and lymphatic system, a first step in the
metastasis of breast cancers [9].
The loss of E-cadherin cell-cell contacts is a hallmark for
the progression of cancers of epithelial origin [26].
Remarkably, the PIPKIg also regulates the ability of epithe-
lial cells to assemble E-cadherin-based cell-cell contacts
[16]. This occurs by an association of PIPKIgi2 with E-cad-
herin and the recruitment of specific clathrin adaptors
required for basolateral and endocytic trafficking by an
association with the PIPKIgi2 C-terminus. A loss of PIPKIg
expression leads to a loss of E-cadherin targeting to the
plasma membrane and a loss of E-cadherin-based cell-cell
contacts [16]. Thus, PIPKIg regulates the plasma mem-
brane targeting of E-cadherin-based cell-cell contacts and
the polarization of epithelial cells. The positioning of the
PIPKIg as a regulator of both E-cadherin cell-cell contact
assembly and growth factor stimulated cell migration posi-
tions the PIPKIg as a key-signaling molecule in physiologi-
cal functions that are fundamental to the metastasis of
cancers of epithelial origin.
In spite of the increasing evidence indicating that PIP-
KIg plays a crucial role in cell migration so that it is
likely implicated in cancer metastasis, the pathological
correlation between the lipid kinase and cancer progres-
sion remains uninvestigated. Here, we analyzed breast
carcinomas via tissue microar r a ya n a l y s e sf o rt h el e v e l s
of PIPKIg and demonstrated a significant inverse corre-
lation between strong positive PIPKIg expression and
overall survival. In addition, the requirement of PIPKIg
for the migration, invasion, and growth of breast cancer
cells has been confirmed using in vitro models.
Materials and methods
Antibody
Polyclonal PIPKIg anti-serum was generated from rabbit
(Covance, Princeton, NJ, USA) using purified His-tagged
PIPKIg. Anti-serum was purified on an affinity column
generated by coupling recombinant C-terminus of PIP-
KIg to cyanogen bromide-activated Sepharose 4B
(Sigma-Aldrich, Saint Louis, MO, USA) as described
[17,25,27]. The affinity-purified antibody recognizes
both PIPKIgi1 and PIPKIgi2.
Constructs
The siRNA sequence targeting PIPKIg is 5’-GGACCUG-
GACUUCAUGCAG-3’. The sequence of control
scrambled siRNA is 5’-GUACCUGUACUUCAUGCAG-
3’. Oligonucleotide sequences used for generation of
short hairpin RNA (shRNA) specific for PIPKIg were:
GCCACCTTCTTTCGAAGAA (PIPKIg shRNA) and
GCCTTCTTCGCTAAACGAA (Control shRNA). Gen-
eration of replication-defective infectious viral particles
and the transduction of the cells were carried out fol-
lowing the protocol provided by Addgene (Addgene
Inc., Cambridge, MA, USA). In brief, synthesized oligo-
nucleotides were annealed and cloned into HpaI and
XhoI sites of pLL3.7 vector (Addgene Inc., Cambridge,
MA, USA). Stabl3 competent cells (Invitrogen, Carlsbad,
CA, USA) were used for transformation and DNA puri-
fication to minimize the mutagenesis. The integrity of
lentiviral vector-containing cloned shRNA sequences
were validated by DNA sequencing.
Cell cultures and transfection
MDA-MB-231 and MDA-MB-435S cells were cultured
using DMEM supplemented with 10% FBS. SKBR3 cells
were cultured in DMEM/F12 with 10% FBS. For siRNA
transfection, cells were transfected with Oligofectamine
(Invitrogen, Carlsbad, CA, USA) following the manufac-
turer’s instructions.
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A tissue microarray was constructed out of 438 archival
invasive breast carcinoma samples at Vancouver General
Hospital. These cases were collected between 1974 and
1995. Ethics board approval was obtained for all cases.
Patients’ demographics, pathological features of the
tumors and expression of various biomarkers have been
reported previously [28]. In brief, median age of the
patients at the moment of diagnosis was 61.5 years;
median survival time was 11.9 years. Histological distri-
bution included 379 infiltrating ductal carcinoma, 41
infiltrating lobular carcinoma and 8 special types.
Three tissue microarray blocks were assembled using a
manual tissue microarrayer (Beecher Instruments, Inc.,
Silver Springs, MD, USA) from formalin fixed paraffin-
embedded tissue as described previously [29]. Tissue sec-
tions (4 μm thick) were cut from the donor blocks and
stained with hematoxylin and eosin for tissue review.
Representative areas of tumor were circled on the slides
and corresponding donor blocks; duplicate 0.6 mm cores
were taken from these blocks and inserted into three
recipient blocks. Sections (4 μm thick) were cut from the
recipient blocks and deparaffinized with CitriSolve and
dehydrated through three alcohol changes. Antigen
retrieval was performed using a steamer for 30 minutes
in 0.1 M citrate buffer (pH 6.0). After that, sections were
rinsed with PBS three times for five minutes each time.
Hydrogen peroxide and serum free protein block (Dako,
Carpenteria, CA, USA) were used to block endogenous
peroxidases and prevent non-specific protein binding.
Sections were then incubated with anti-PIPKIg antibody
(0.5 μg/ml) in a sealed immunochamber overnight at 4°C
and Dako Envision anti-rabbit secondary antibody was
applied at room temperature for 30 minutes. The
NovaRed Substrate Kit (Vector Labs, Burlingame, CA,
USA) was used to visualize the protein. Slides were then
counterstained with hematoxylin and mounted.
Digital image database
The hematoxylin and eosin and immunohistochemistry
images of all cores used in this study are publicly avail-
able at the companion site [30]. The site was con-
structed using a GPEC database and a Java applet
provided by Bacus Laboratories, Inc (Bacus Laboratories,
Inc., Lombard, IL, USA). All the slides were scanned
with a BLISS scanner (Bacus Laboratories, Inc., Lom-
bard, IL, USA), and posted on the site. WebSlide Brow-
ser for Windows (Bacus Laboratories, Inc., Lombard, IL,
USA) can be used for viewing preview images of the
arrays and images of individual cores.
Cell migration assay
The assays were performed in modified Boyden chamber
transwell (Neuroprobe, Gaithersburg, MD, USA) as
described [31,32]. The membrane was pre-coated with
type I collagen (10 μg/ml). Per well, 50,000 cells were
applied. Chemotaxis assays were performed at 37°C in
humidified air with 5% CO2 f o rf o u rh o u r s .C e l l s
migrated through to the underside of the membrane
were counted in five high power fields, in a blinded
fashion. The migration index for each experiment was
calculated as the mean number of cells that migrated
toward medium-containing 1% FBS divided by the mean
number of cells that migrated toward medium-contain-
ing BSA only.
Invasion assay
Matrigel-coated Transwells (BD Bioscience, San Jose,
C A ,U S A )w e r ei n c u b a t e dw i t hD M E Mf o rf o u rh o u r s
and 5 × 10
4 cells were plated in the upper chambers.
The lower chambers contained 1% FBS conditioned
DMEM. The inserts were incubated at 37°C in humidi-
fied air with 5% CO2 for 24 hours. The cells that had
invaded the lower surface of the membrane were fixed
with 4% polyformaldehyde and stained with 0.2% crystal
violet. The number of cells that had invaded was quanti-
fied by counting random fields using a light microscope.
Cell proliferation assay
MDA-MB-231, MDA-MB-435S, or SKBR3 cells infected
with lentivirus containing either control shRNA or PIP-
KIg shRNA were seeded into 12-well culture plates at a
density of 1000 cells/well. Then, manual cell counting
was performed every two days for eight days.
Statistical analysis
We performed Kaplan-Meier survival analysis using log-
rank test to determine differences in survival of the
patients with different levels of PIPKIg protein expres-
sion. Breslow test was also used to emphasize survival
differences in the first 5 to 10 years of the follow up.
The alpha level was determined as 5%. All the tests
were two-sided. Spearman’s correlation was utilized to
estimate correlations between PIPKIg protein content
with that of other biomarkers and clinical prognostic
factors.
Results
Expression of PIPKIg in breast carcinomas
The cellular functions of PIPKIg suggest the potential
for roles in epithelial cancer progression. To explore the
potential that PIPKIg may correlate with disease pro-
gression and outcome we began to assess the content of
PIPKIg in a well-characterized tissue microarray of
breast cancer patients. For this approach we used well-
characterized antibody that specifically detect all splice
variants of the PIPKIg as described in Materials and
Methods. As a control, PIPKIg expression was knocked
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epithelial (MCF10a) or carcinomas cell lines and this
resulted in a loss of protein by western blotting and a
loss of the immunostaining in these cells [16,25].
Normal breast tissues show strong staining for E-cad-
herin epithelia cells lining the ducts and PIPKIg also
shows strong staining of these cells (Figure 1a). To
assess how the PIPKIg expression changes within breast
cancers we have screened a breast cancer tissue micro-
array. The expression of PIPKIg in breast carcinomas
was demonstrated via tissue microarray that was con-
structed out of 438 archival invasive breast carcinoma
samples at the Vancouver General Hospital [33]. Of the
438 breast carcinoma represented on the tissue microar-
ray, 330 specimens (75.3%) were considered interpreta-
ble. As shown in the lower panels of Figure 1a, in
Figure 1 Expression of PIPKIg in breast carcinomas. (a) Shown is H&E, E-cadherin and type I gamma phosphatidylinositol phosphate kinase
(PIPKIg) staining of normal breast tissue (top). Breast carcinomas that show a loss of both E-cadherin and membrane PIPKIg (middle). A fraction
of carcinomas that show both a mistargeting of E-cadherin and a loss of PIPKIg (bottom). (b) Expression of PIPKIg in breast carcinomas. (Left
panel) Representative breast carcinomas stained negative for PIPKIg. (Middle panel) Representative breast carcinomas stained weakly positive for
PIPKIg. (Right panel) Representative breast carcinomas stained strong positive for PIPKIg. (c) Immunohistochemical staining of breast tumor tissue
for human epidermal growth factor receptor (HER-1) and PIPKIg. The panels on the top or on the bottom are from the same tumors. The top
panels show strong expression of HER-1 and PIPKIg, whereas the bottom shows weak staining for both antigens.
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PIPKIg staining. The bottom panel of Figure 1a shows
that in a fraction of tumors E-cadherin was expressed
but not targeted to the plasma membrane and these
tumors also lost PIPKIg. These combined data are
shown statistically in Table 1.
In Figure 1b, examples of the different PIPKIg staining
of breast tumors are shown. The slides were scored as
‘negative’ if no PIPKIg staining was detected, ‘weak
staining’ if there was any amount of weak membranous
staining and/or strong membranous staining in less than
50% of tumor cells, and ‘strong staining’ if there was
strong membranous staining in 50% or more carcinoma
cells. Among the 358 specimens analyzed, 149 speci-
mens were PIPKIg staining negative (41.6%), 144 speci-
mens were PIPKIg staining weakly positive (40.2%), and
65 specimens were PIPKIg staining strongly positive
(18.2%) (Table 2).
Survival analysis
To investigate if PIPKIg tissue content correlates to
breast cancer prognosis, Kaplan-Meier survival curves
were generated using PIPKIg antibody staining. As
shown in Figure 2a, these curves show that strong posi-
tive PIPKIg expression was correlated to poor outcome
(Log Rank chi-squared = 6.078, P = 0.014; Breslow chi-
squared = 7.454, P = 0.006). It indicates that PIPKIg
expression is inversely correlated to the survival of
breast cancer patients. To further define the correlation
of PIPKIg expression with breast cancer prognosis,
patients were stratified based on the lymph node status.
Kaplan-Meier survival curves were generated for lymph
node negative and lymph node positive. As shown in
Figure 2b, there was no significant difference in survival
of the patients with PIPKIg strong positive and weak
positive or negative tumor in lymph node negative sub-
set (Log Rank chi-squared = 1.01, P = 0.315; Breslow
chi-squared = 0.945, P = 0.331). In the lymph node
positive subset, the longer term survival difference was
not significant in the log-rank test (Log Rank chi-
squared = 2.154, P =0 . 1 4 2 ,F i g u r e2 c ) ;h o w e v e r ,t h e5 -
and 10-year survival rate of PIPKIg strong positive
patients is significantly lower than PIPKIg negative or
weakly positive patients and had trend towards signifi-
cance in Breslow test (Breslow chi-squared = 3.267, P =
0.071, Figure 2c). Considering that the median age of
the patients at the moment of diagnosis is 61.5 years,
the longer-term survival as 20 or 25 years may not
clearly reflect the survival of breast cancer because it is
very close to the normal average human life limit. The
5- and 10-year survival rate difference supports that
PIPKIg expression is inversely correlated to the survival
of breast cancer patients.
Correlation of PIPKIg expression with breast cancer
biomarkers
To further characterize PIPKIg expression in breast can-
cer, Spearman’s correlation was used to demonstrate the
correlation of PIPKIg expression with clinical character-
istics such as lymph nodal status, tumor size and Not-
tingham tumor grade. As shown in Table 1, PIPKIg
expression does not correlate significantly with lymph
nodal status and tumor size. There is a weak significant
correlation with the Nottingham grade.
PIPKIg expression was correlated with the expression
of some established breast cancer biomarkers on a tissue
microarray. From this analysis there was a correlation
between the loss of PIPKIg with loss of E-cadherin
expression and plasma membrane targeting. It is
Table 1 Correlation of expression of PIPKIg protein with different biomarkers
Biomarker PIPKIg negative and weak vs. strong staining
Spearman’s correlation coefficient P value Number of cases
E-cadherin negative vs. weak and strong staining 0.106 0.046 351
ER at 1% cut-off point -0.256 0.000003 327
PR at 1% cut-off point -0.298 0.000001 256
EGFR (HER1) negative vs. weak and strong staining 0.262 0.000003 306
HER2/neu 0.171 0.003 309
Nottingham Grade 0.185 0.001 346
Tumour size 0.025 0.648 349
Nodal status 0.012 0.828 314
EGFR = epidermal growth factor receptor; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; PIPKIg = type I gamma
phosphatidylinositol phosphate kinase; PR = progesterone receptor.
Table 2 Number of breast carcinomas cases stained with
negative, weakly positive and strong positive PIPKIg
PIPKIg staining Cases % of total cases
negative 149 41.6
weakly positive 144 40.2
strong positive 65 18.2
PIPKIg = type I gamma phosphatidylinositol phosphate kinase.
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Page 5 of 11Figure 2 Kaplan-Meier survival curves for PIPKIg staining, with time given in years. (a) The entire cohort of patients. (b) Lymph node
negative patients. (c) Lymph node positive patients. PIPKIg = type I gamma phosphatidylinositol phosphate kinase.
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E-cadherin and modulates E-cadherin trafficking [16].
Epidermal growth factor receptor (EGFR)/human epi-
dermal growth factor receptor (HER) family receptors
are often overexpressed in breast cancers and are used
as breast cancer biomarkers [34]. Interestingly, our
results show that both HER1 (EGFR) and HER2/neu
expression are correlated with PIPKIg expression (Table
1). EGFR/HER family receptors play key roles in breast
cancer metastasis and their expression are correlated
with worse prognostic patient survival rates [35,36]. The
correlation of PIPKIg with EGFR/HER family receptors
is consistent with the finding that PIPKIg expression is
inversely correlated to the survival of breast cancer
patients. In addition, the results of tissue microarrays
show that the expression of PIPKIg is inversely corre-
lated to estrogen receptor (ER) and progestin receptor
(PR). ER and PR status are important for distinguishing
different breast cancer subtypes and they are critical for
ER
+ or PR
+ breast cancer cell growth [37,38]. Our find-
ing is the first time to discover a correlation between
PIPKIg with ovarian hormone receptors ER and PR.
PIPKIg regulates growth factor stimulated breast cancer
migration and invasion
Previously, it has been shown that PIPKIg is required for
growth factor-induced HeLa (Helen Lane) cell migration
[25]. As PIPKIg expression is inversely correlated to the
survival of breast cancer patients, to regulate cancer cell
metastasis might be one of the mechanisms for PIPKIg
function in breast cancer. In order to verify this possibi-
lity, the effect of PIPKIg knockdown on two breast can-
cer cell lines, MDA-MB-231 and MDA-MB-435S,
migration and invasion was demonstrated. As shown in
Figure 3a, PIPKIg-specific siRNA could specifically
knockdown expression of PIPKIg in MDA-MB-231 or
MDA-MB-435S cells, compared with the actin control.
The effect of PIPKIg-knockdown on breast cancer cell
migration was quantified using a modified Boyden
chamber transwell assay. As shown in Figure 3b, the
knockdown of PIPKIg blocked migration of both MDA-
MB-231 and MDA-MB-435S. To investigate the effect
of PIPKIg-knockdown on breast cancer cell invasion, a
Matrigel invasion assay was used. As shown in Figure
3c, the knockdown of PIPKIg also blocked invasion of
both MDA-MB-231 and MDA-MB-435S.
PIPKIg regulates breast cancer cell growth
To further investigate the role of PIPKIg in the patho-
genesis of breast cancer progression, lenti-virus-vector-
based PIPKIg shRNA was used to establish PIPKIg-
knockdown stable cell lines in MDA-MB-231, MDA-
MB-435S, and SKBR3 cells. The knockdown of PIPKIg
expression in these stable cell lines was confirmed by
western blot as shown in Figure 4. The effect of PIPKIg-
knockdown on breast cancer cell growth was then deter-
m i n e d .A ss h o w ni nF i g u r e4 ,P I P K I g-knockdown
decreased cell growth of MDA-MB-231, MDA-MB-
435S, and SKBR3 cells (Figures 4a to c). This result indi-
cates an important role of PIPKIg in breast cancer cell
proliferation and is consistent with the finding that PIP-
KIg expression is inversely correlated to the survival of
breast cancer patients.
Discussion
Here, we have shown that the expression of PIPKIg is
inversely correlated to the survival of breast cancer
patients, indicating a potential prognostic value of PIP-
KIg. Consistently, PIPKIg is required for breast cancer
cell migration, invasion, and proliferation. All these
results support the fact that PIPKIg plays an important
role in breast cancer progression.
Overexpression of the EGFR has been shown to corre-
late with metastasis and poor prognosis of breast cancer
[39]. Our results show that EGFR expression is corre-
lated to PIPKIg expression in breast cancer cells, which
hints that EGFR and PIPKIg may cooperate to facilitate
breast cancer metastasis. Upon EGF stimulation, EGF-
induced phosphorylation of PIPKIg causes a disassembly
of the phospholipase C-g1-PIPKIg complex and this
could enhance PI4,5P2 accumulation and thus enhances
talin assembly into adhesions and this in turn would
facilitate the protrusion formation and stabilization of
adhesions, which is required for cell migration [25].
Our results demonstrate that PIPKIg is not only
required for breast cancer cell migration but also for
breast cancer cell invasion. During invasion, cancer cells
form actin-containing protrusions, called invadopodia,
that extend into the extracellular matrix and participate
in extracellular matrix degradation [40]. ADP-ribosyla-
tion factor 6 (ARF6) is a regulator of invadopodia for-
mation and cell invasion [41] and ARF6 directly
activates PIPKIg [42]. It is plausible that PIPKIg plays a
role in invadopodia formation by production of PI4,5P2
that regulates actin filament dynamics via cofilin, a-acti-
nin, and vinculin.
The PIPKIg expression is correlated with E-cadherin
in our tissue microarray results. It is consistent with the
role of PIPKIg in regulating E-cadherin trafficking. PIP-
KIg binds directly to E-cadherin and recruits clathrin
adaptor complexes AP1B to the E-cadherin-PIPKIg com-
plex and this controls the targeting of E-cadherin to the
basolateral membrane [14,16]. The loss of PIPKIg results
in the loss of E-cadherin targeting to the plasma mem-
brane and a loss of epithelial cell polarization. The PIP-
KIg-interacting region in E-cadherin has some
overlapping with b-catenin-binding domain [16]. PIPKIg
may regulate E-cadherin-b-catenin interaction and then
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tion of b-catenin correlated significantly with cyclin D1
expression, and that high b-catenin activity significantly
correlated with poor prognosis of the patients and was a
strong and independent prognostic factor in breast can-
cer [43]. PIPKIg may regulate breast cancer progression
via E-cadherin-b-catenin signal pathway.
Breast cancers are heterogeneous in their ER and PR
status and display different response to tamoxifen treat-
ment [44]. A study on the cellular phenotypes of breast
cancer tumors in 19,541 white women with node-nega-
tive disease showed that ER+/PR+ is the most common
phenotype of breast cancer constituting 66% of the
tumors, followed by ER-/PR- (19%), ER+/PR- (12.5%),
and ER-/PR+ (3.4%). Among these different tumors,
ER-/PR- tumors are associated with the worst cancer-
specific survival and are resistant to tamoxifen treatment
[45]. Our results show that higher expression of PIPKIg
correlates to lower expression of ER and/or PR and cor-
relates to lower patient survival rates. It is consistent
Figure 3 Knockdown of PIPKIg blocks breast cancer cell line migration and invasion. MDA-MB-231 or MDA-MB-435S cells were transfected
with control siRNA, or type I gamma phosphatidylinositol phosphate kinase (PIPKIg) specific siRNA separately as indicated. (a) Expression of
PIPKIg and actin were detected by their specific antibodies. (b) FBS (1%) induced migration of MDA-MB-231 and MDA-MB-435S cells. (c) FBS (1%)
induced invasion of MDA-MB-231 and MDA-MB-435S cells.
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poor breast cancer prognosis. Although it is not clear if
PIPKIg could directly modulate ER or PR expression
and if PIPKIg could regulate ER or PR signaling, our
results provide evidence that PIPKIg correlates with
ovarian hormone receptors status. It is worthy to
demonstrate the possible role of PIPKIg in regulating
ovarian hormone pathways in breast cancer progression.
Conclusions
The inverse correlation between strong PIPKIg expres-
sion and overall patient survival is consistent with the
finding that PIPKIg is required for breast epithelial cell
adherent junction assembly, growth factor stimulated
migration, invasion, and proliferation. This study pro-
vides evidence of the pathological significance of PIPKIg
in breast cancer progression.
Figure 4 PIPKIg expression is required for rapid cell proliferation in breast cancer cells. Lentiviral vector was used to generate the stable
knockdown of type I gamma phosphatidylinositol phosphate kinase (PIPKIg) in breast cancer cell lines as described in “Material and methods”.
Decreased expression of PIPKIg was assessed by using PIPKIg specific antibody. Cells infected with either Control short-hairpin RNA (shRNA) or
PIPKIg shRNA were seeded into 12-well culture plates at a density of 1000 cells/well. Manual cell counting was performed every two days for the
eight days. The cell numbers were counted from at least three wells for each cell type and expressed as mean ± standard deviation from one
representative experiment. (a) MDA-MB-231 cells. (b) MDA-MB-435S cells. (c) SKBR3 cells.
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